Impaired fasting glucose MedDRA version: 9.1 Level: LLT Classification code 10056997 Term: Impaired fasting glucose
Conditions
Interventions
Trade Name: Glucophage SR 500mg
Pharmaceutical Form: Tablet
Sponsors
Hull and East Yorkshire Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Previous participation in RIMON_R_00961 Impaired fasting glucose LFT less than 200% reference range Serum Creatinine less than 150 mmol/l Willing to allow GP to be informed Able to give consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Not having previously been diagnosed with diabetes Previously been treated with antidiabetes medication Not able to give consent or allow GP to be informed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Does metformin reduce weight regain and reduce the risk of developing diabetes and heart disease in subjects with impaired fasting glucose who have previously been treated for weight loss with lifestyle advice and rimonabant/placebo?;Secondary Objective: Does metformin have a greater effect in subjects previously treated with rimonabant when compared to placebo? Is treatment with metformin following rimonabant more clinically and cost effective than treating with rimonabant alone?;Primary end point(s): Weight, no weight gain over 12 months Reduced insulin resistance Improved lipid profile | — |
Countries
United Kingdom
Outcome results
None listed